Reproducibility of cognitive endpoints in clinical trials:lessons from neurofibromatosis type 1 by ,
                                                                    
University of Dundee
Reproducibility of cognitive endpoints in clinical trials
Published in:
Annals of clinical and translational neurology
DOI:
10.1002/acn3.50952
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
(2019). Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Annals of
clinical and translational neurology, 6(12), 2555-2565. https://doi.org/10.1002/acn3.50952
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jan. 2021
RESEARCH ARTICLE
Reproducibility of cognitive endpoints in clinical trials:
lessons from neurofibromatosis type 1
Jonathan M. Payne1,2 , Stephen J. C. Hearps1, Karin S. Walsh3, Iris Paltin4, Belinda Barton5,6,7,
Nicole J. Ullrich8 , Kristina M. Haebich1, David Coghill1,2, Gerard A. Gioia3, Alan Cantor9, Gary
Cutter10, James H. Tonsgard11, David Viskochil12, Celiane Rey-Casserly13, Elizabeth K. Schorry14, Joseph
D. Ackerson15, Laura Klesse16, Michael J. Fisher4, David H. Gutmann17 , Tena Rosser18, Roger J.
Packer3, Bruce Korf19, Maria T. Acosta3,20 & Kathryn N. North1,2 for the NF Clinical Trials Consortium
1Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia
2Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
3Center for Neuroscience and Behavioral Medicine, Children’s National Health System, Washington, DC
4Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
5Kids Neuroscience Centre, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia
6Children’s Hospital Education Research Institute, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia
7The University of Sydney Children’s Hospital Westmead Clinical School, University of Sydney, Westmead, New South Wales, Australia
8Department of Neurology, Boston Children’s Hospital, Boston, Massachusetts
9Department of Preventative Medicine, University of Alabama at Birmingham, Birmingham, Alabama
10School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama
11Division of Neurology, The University of Chicago Medicine Comer Children’s Hospital, Chicago, Illinois
12Department of Genetics, University of Utah, Salt Lake City, Utah
13Center for Neuropsychology, Boston Children’s Hospital, Boston, Massachusetts
14Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
15Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama
16Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
17Department of Neurology, Washington University School of Medicine, St Louis, Missouri
18Department of Neurology, Children’s Hospital of Los Angeles, Los Angeles, California
19Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama
20National Institutes of Health, National Human Genome Research Institute, Bethesda, Maryland
Correspondence
Jonathan M. Payne, Murdoch Children’s
Research Institute, Royal Children’s Hospital,
Flemington Road Parkville, VIC 3052 Australia.
Tel: +61 3 9936 6761; Fax: +61 3 8341 6212;
E-mail: jonathan.payne@mcri.edu.au
Funding Information
This work was supported by the United States
Army Medical Research and Materiel
Command, Office of the Congressionally
Directed Medical Research Programs,
Department of Defense Neurofibromatosis
Research Program, Grant Number W81XWH-
05-1-0615.
Received: 3 July 2019; Revised: 31 October
2019; Accepted: 1 November 2019
Annals of Clinical and Translational
Neurology 2019; 6(12): 2555–2565
doi: 10.1002/acn3.50952
Abstract
Objective: Rapid developments in understanding the molecular mechanisms
underlying cognitive deficits in neurodevelopmental disorders have increased
expectations for targeted, mechanism-based treatments. However, translation
from preclinical models to human clinical trials has proven challenging. Poor
reproducibility of cognitive endpoints may provide one explanation for this
finding. We examined the suitability of cognitive outcomes for clinical trials in
children with neurofibromatosis type 1 (NF1) by examining test-retest reliabil-
ity of the measures and the application of data reduction techniques to improve
reproducibility. Methods: Data were analyzed from the STARS clinical trial
(n = 146), a multi-center double-blind placebo-controlled phase II trial of
lovastatin, conducted by the NF Clinical Trials Consortium. Intra-class correla-
tion coefficients were generated between pre- and post-performances (16-week
interval) on neuropsychological endpoints in the placebo group to determine
test-retest reliabilities. Confirmatory factor analysis was used to reduce data into
cognitive domains and account for measurement error. Results: Test-retest reli-
abilities were highly variable, with most endpoints demonstrating unacceptably
low reproducibility. Data reduction confirmed four distinct neuropsychological
domains: executive functioning/attention, visuospatial ability, memory, and
behavior. Test-retest reliabilities of latent factors improved to acceptable levels
for clinical trials. Applicability and utility of our model was demonstrated by
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
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homogeneous effect sizes in the reanalyzed efficacy data. Interpretation: These
data demonstrate that single observed endpoints are not appropriate to deter-
mine efficacy, partly accounting for the poor test-retest reliability of cognitive
outcomes in clinical trials in neurodevelopmental disorders. Recommendations
to improve reproducibility are outlined to guide future trial design.
Introduction
Advances in genetically modified animal models and
induced pluripotent stem cells have allowed detailed exam-
ination of the molecular pathways underlying cognitive
deficits in neurodevelopmental conditions. This in turn has
resulted in candidate molecular targets for therapeutic
drugs, many of which have reversed behavioral phenotypes
in animal models.1–3 Despite a significant number of clini-
cal trials targeting cognitive deficits in patients with genetic
conditions, the vast majority have failed to translate the
encouraging findings from preclinical trials.4 The chal-
lenges of translating targeted treatments in human ran-
domized controlled trials (RCTs) are typified by
neurofibromatosis type 1 (NF1),5–7 an autosomal domi-
nant genetic condition associated with cognitive deficits
affecting 80% of children.8 Preclinical trials have identified
several promising therapeutic targets. Lovastatin normal-
izes synaptic plasticity and rescues the learning phenotype
in Nf1+/ mice by targeting RAS activation,1 while methyl-
phenidate and L-dopa improve attention by normalizing
dopamine homeostasis in an Nf1+/ strain with bi-allelic
inactivation in neuroglial progenitor cells.9 Similarly, phar-
macological blockade of Pak1 function within the amyg-
dala rescues social deficits in Nf1+/ mice10 and the HCN
channel agonist lamotrigine rescues electrophysiological
deficits by normalizing excitability of inhibitory interneu-
rons.11 Despite the optimism provided by these preclinical
studies, attempts at translating findings to human clinical
RCTs have been mixed (Table 1).5–7,12–16 While benefits of
methylphenidate for attention deficit/hyperactivity disorder
(ADHD) have been reported,16 and a very small study has
suggested an effect of lovastatin on learning and memory,15
three larger trials have failed to demonstrate any cognitive
benefits of statin therapy.5–7
Translation from mouse studies to effective human
clinical trials has proven difficult.4,17 Potential explana-
tions for this include inadequacy of animal models to
recapitulate the complexity of the human disease state18,19
and the frequent use of small sample sizes,4 a common
issue of RCTs in rare genetic conditions. It is also vital
that cognitive endpoints are sensitive and reliable.20 Here,
we evaluated the suitability of various cognitive and
behavioral endpoints for clinical trials in children with
NF1 by analyzing data from the largest clinical trial for
NF1-related cognitive deficits; the NF Clinical Trials Con-
sortium’s STAtin Randomized Study (STARS). This
multicenter (11 sites), double-blind, randomized, placebo-
controlled, parallel arm trial evaluated the efficacy of
lovastatin for cognitive and behavioral deficits in children
with NF1.5 Similar to a previous study,20 our initial aims
were to (1) determine the severity of deficits on cognitive
and behavioral outcomes at baseline and (2) examine the
test-retest reliability of outcome measures after the 16-
week treatment period. However, we extend this by also
(3) investigating the utility of data reduction using confir-
matory factor analysis (CFA) to improve psychometric
properties of cognitive and behavioral outcomes, and (4)
re-analyzing efficacy data using CFA-derived latent
variables.
Methods
Participants
We analyzed data from the 144 children randomized in
the STARS clinical trial.5 Participants were treated with
lovastatin (n = 74, mean age 11.5 years, 58% male) or
placebo (n = 70, mean age 11.7 years, 62% male). Partici-
pants satisfied the clinical diagnostic criteria for NF1,21
were aged between 8 and 15 years at screening, and
demonstrated impaired performance on at least one pri-
mary outcome (≥1 SD below population mean). Exclu-
sion criteria included full scale IQ < 70, symptomatic
CNS pathology, significantly impaired vision/hearing,
insufficient comprehension of English, low baseline total
cholesterol (<90 mg/dL), and medications contraindicated
on lovastatin. Children on a stable dose of stimulant
medication (one month prior to screening and for study
duration) were considered eligible.
The protocol was approved by the institutional review
board at each site. The study was performed in accor-
dance with the Declaration of Helsinki and Good Clinical
Practice guidelines and was registered at clinicaltrials.gov
(NCT00853580). Written informed consent was obtained
from all parents/guardians before study entry.
Outcome measures
Efficacy outcomes were administered by psychologists at
baseline and after 16-weeks of treatment and have previ-
ously been described in detail.5 In brief, primary outcome
measures were the Paired Associate Learning (PAL) test
from the Cambridge Neuropsychological Automated
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Battery (CANTAB) assessing visuospatial learning22 and
Score from the Test of Everyday Attention for Children
(TEA-Ch) measuring sustained attention.23 Secondary
endpoints assessed attention, executive function and visu-
ospatial skills, using Spatial Working Memory (SWM),
Stockings of Cambridge (SOC), and the Stop Signal Task
(SST) from the CANTAB, Sky Search, Sky Search DT and
Creature Counting from the TEA-Ch, the Conners’ Con-
tinuous Performance Task-II (CPT-II), Controlled Oral
Word Association Test, Judgment of Line Orientation
task, and Wechsler Object Assembly. In addition, parent
behavioral rating scales assessed ADHD symptoms with
the Conners-3, executive functions via the Behavior Rat-
ing Inventory of Executive Functions (BRIEF), internaliz-
ing behaviors on the Behavior Assessment System for
Children-II (BASC-II), and psychosocial quality of life
with the PedsQL. Participants also completed self-report
versions of the BASC-II and PedsQL.
Data analysis
Unless stated otherwise, the complete case data set was
used for all analyses. Baseline scores for all participants
were used to establish the presence of pre-treatment
cognitive and behavioral deficits. To allow direct com-
parisons between the various test scores, each standard-
ized outcome was converted into a z-score such that 0
equals the reference group average with a standard devi-
ation of 1. Differences between the NF1 group and nor-
mative reference data were tested using one-sample t-
tests. To determine test-retest reliability of outcome
measures, we examined associations between pre- and
post-treatment scores of the placebo group using intra-
class correlations.
We then conducted a rational reduction of cognitive
and behavioral outcomes by creating a series of CFA
models to determine the best-fitting model for the dif-
ferent cognitive domains (executive functioning/atten-
tion, memory, visuospatial) and behavior. CFA was
chosen over exploratory factor analysis because it is a
top-down, hypothesis-driven variant of structural equa-
tion modelling that is used to examine the expected
connections between variables, treating each observed
measure as one of multiple fallible manifest indicators
of an underlying latent (i.e., unmeasured) construct.
CFA models allow for random and systematic measure-
ment error in the observed variables and the latent con-
structs can be interpreted with the measurement error
taken into account. Scores were transformed prior to
CFA such that a positive score reflected superior perfor-
mance. The maximum likelihood method was used, and
model assumptions examined (i.e., outliers, multivariate
normality, linearity). Power calculations indicatedTa
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approximately 90% power to achieve statistical signifi-
cance in our proposed CFA model. Several models were
tested and the best determined by the best overall fit
indices including the v2 value, normed v2 (divided by
the model degrees of freedom), Comparative Fit Index
(CFI), and the root mean square error of approximation
(RMSEA). Smaller v2 (and non-significant P-value),
normed v2(<3) and RMSEA (<0.06) values and larger
CFI (>0.9) values indicate a better fit. Standardized fac-
tor loadings of the best fitting model at baseline were
used to calculate the scores for the latent factors at
baseline and post-treatment.
As before, we determined test-retest reliability of latent
factors by examining associations between pre- and post-
treatment scores of the placebo group using intra-class
correlations. We then re-examined the efficacy of lovas-
tatin using the CFA-derived latent factors, comparing
post-treatment scores of lovastatin and placebo conditions
using analysis of covariance, adjusting for baseline scores.
These intention to treat (ITT) analyses utilized data from
participants with complete baseline data, applying multi-
ple imputation for cases with missing 16 week data. Fol-
low-up scores were imputed from baseline values, child
age and sex, with 20 replications. Effect sizes were calcu-
lated (Cohen’s d) to determine the magnitude of the
group comparisons such that an effect size of 0.3 is small,
0.5 medium and 0.8 large.24 All analyses were conducted
in Stata IC (version 13.1).
Results
Summary baseline results for the intention to treat popu-
lation are shown in Table 2. With the exception of child-
reported internalizing behaviors (P = 0.459), baseline
mean scores were significantly poorer than normative ref-
erence data (all, P < 0.001), confirming the presence of
cognitive and behavioral deficits on these measures.
Test-retest reliability
Intra-class correlations between observed test values at
baseline and post-treatment (week-16) for participants
in the placebo condition are shown in Table 2. These
test-retest effects allow examination of the stability of
cognitive and behavioral outcomes of an inactive treat-
ment within a realistic clinical trial setting. Higher cor-
relations indicate higher stability and superior test-retest
reliability of the outcome measure between pre-post
assessments. While there are few standards for judging
the minimum acceptable value for a test-retest reliability
estimate,25 reproducibility coefficients are typically con-
sidered adequate if greater than 0.7.26 By these stan-
dards, test-retest reliability of the two primary outcomes
was poor, with PAL and Score falling well below ade-
quate levels (both, r < 0.40). Indeed, most secondary
cognitive outcomes fell below adequate levels including
widely used computerized tasks specifically designed to
assay reliable change in clinical trials settings, including
SWM and SST from the CANTAB. The SOC task in
particular was very poor (r = 0.10). More traditional
cognitive assessments tended toward higher pre-post
correlations, but only the COWAT and JLO tasks
demonstrated adequate reliabilities (both, r > 0.72). On
the whole, behavioral questionnaire ratings tended
towards higher pre-post correlations than cognitive out-
comes. Parent-reported ADHD symptoms on the Con-
ners-3 approached adequate levels, while reproducibility
of parent-reported executive behaviors on the BRIEF
was good. Parent and child-reported internalizing prob-
lems on the BASC-2 were adequate and psychosocial
quality of life was just below acceptable levels for parent
and child-report.
Confirmatory factor analysis
To reduce the number of variables and account for mea-
surement error associated with observed variables, we
performed a series of CFAs, based on theoretical models,
using the cognitive factors of (1) executive functioning/
attention, (2) memory, (3) visuospatial ability, and (4)
general behavior on the complete-case population
(n = 104) (Table S1). The best-fitting four-factor model
is shown in Figure 1. Fit of this four-factor model was
acceptable (v2 (154) = 181.59, P = 0.06; normed
v2 = 1.18; CFI = 0.95; RMSEA = 0.041, P = 0.73), model
assumptions met, and factor loadings were significant
(all, P < 0.05). Two cognitive variables (SOC mean num-
ber of moves and CPT commission errors) were excluded
from the final model as their inclusion resulted in a poor
fit (Table S2).
Results of pre-post intra-class correlations of the four
latent cognitive and behavioral factors are shown in
Table 3. As before, only the placebo condition was ana-
lyzed, employing ITT analysis with multiple imputation
applied to those missing 16 week data. Results revealed
noteworthy increases in test-retest reliability for the four
latent variables compared to observed values reported in
Table 2. The executive functioning/attention variable
returned excellent reproducibility (r = 0.83), compared
with the test–retest reliabilities of the eight observed cog-
nitive values loading on the latent factor (range, 0.30-
0.82). Pre-post correlations for the visuospatial and
behavioral latent factors were also acceptable. The mem-
ory factor, consisting of PAL and SWM variables, fell
slightly below the level of reliability considered adequate
for clinical trials (r = 0.66).
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Having established superior psychometric properties of
the CFA-derived latent variables, efficacy data from the
STARS clinical trial were reanalyzed using the latent vari-
ables (Table 4). Again, this ITT analysis incorporated
multiple imputed 16 week data where missing. While the
analysis revealed no significant effect of lovastatin on any
of the latent variables (all, P > 0.17), the consistency of
effect sizes for the latent variables was considerably
increased compared to those reported for the observed
test scores. For example, lovastatin demonstrated a similar
positive but non-significant effect on all three CFA-
derived cognitive variables (d range; 0.24–0.26). In com-
parison, the observed test scores revealed noticeably more
variation (d range; 0.23 to 0.36).5
Discussion
The selection of reliable outcomes that are sensitive to
change is critical to the interpretation of any clinical trial,
and is a particularly important issue for cognitive studies.
Unreliable measures adversely affect the ability to detect
positive responses to treatments and may explain the
translational failure of mechanism-based clinical trials
across a wide number of genetic conditions.4 Here we
present a detailed and methodical reexamination of the
outcome data from STARS to advance the design of
future cognitive clinical trials.
First, consistent with previously published data,8,20 we
demonstrated broad-ranging cognitive and behavioral
Table 2. Total sample raw and standardized summary statistics for outcomes, and test–retest results within the placebo group.
Total study population Test-retest effects in placebo group only
Baseline Baseline 16 weeks
N Mean SD Z-score SD n Mean SD Mean SD ICC
Cognitive test
PAL1 143 16.1 19.4 0.7 1.35 57 18.1 16.5 12.2 12.1 0.32
SWM1 139 47.1 16.2 0.9 0.9 57 48.6 16.0 42.0 16.9 0.61
SWM strategy1 139 36.7 4.4 0.7 1.0 57 37.0 4.7 35.5 5.5 0.51
SOC1 136 7.9 1.3 0.5 1.1 53 8.1 1.3 7.9 1.4 0.10
SST1 135 252.2 89.8 N/A N/A 53 235.7 79.5 228.1 94.7 0.51
Score1 136 5.9 2.2 1.7 0.7 55 5.8 2.5 6.7 2.6 0.39
Sky search1 137 4.7 1.9 0.7 1.0 55 5.2 2.2 4.6 2.2 0.63
Sky search DT1 136 10.0 17.2 1.7 1.3 55 10.3 20.2 6.5 11.4 0.30
Creature counting1 137 3.9 2.2 0.8 1.2 55 3.8 2.3 4.6 1.9 0.56
CPT omission2 135 59.7 15.2 1.0 1.5 51 60.5 16.2 63.5 17.7 0.62
CPT commission2 135 55.6 9.1 0.6 0.9 51 57.0 6.1 55.8 7.1 0.68
CPT RT2 135 55.0 14.2 0.5 1.4 51 53.6 12.9 55.1 15.1 0.70
COWAT1 137 21.8 8.8 N/A N/A 55 21.7 9.2 23.2 9.3 0.82
Object assembly3 137 6.8 3.1 1.0 1.0 55 7.3 2.9 7.7 3.3 0.66
JLO1 135 14.9 6.2 N/A N/A 54 14.5 5.7 16.4 6.3 0.73
Behavioral questionnaires
ADHD inattentive2 137 64.7 13.4 1.5 1.4 55 63.8 14.1 61.3 13.1 0.65
ADHD hyperactive/impulsive2 137 63.8 14.5 1.4 1.6 55 63.5 15.3 62.9 16.9 0.68
BREIF BRI2 135 57.5 12.8 0.8 1.3 55 56.4 13.5 54.9 12.6 0.79
BRIEF MCI2 135 63.5 11.4 1.4 1.2 55 63.2 11.9 60.2 12.1 0.78
BRIEF GEC2 134 62.3 11.7 1.2 1.2 55 61.6 12.1 58.9 12.5 0.80
Internalizing problems – parent2 133 54.4 12.3 0.4 1.2 54 54.3 12.0 52.9 11.5 0.72
Internalizing problems – child2 132 50.8 9.4 0.1 1.0 52 51.4 9.1 49.4 8.6 0.78
PedsQL psychosocial – parent4 133 64.0 17.0 1.0 1.2 54 64.6 18.8 68.1 17.1 0.65
PedsQL psychosocial – child4 132 65.2 16.5 1.0 1.1 54 62.7 17.1 67.2 17.7 0.69
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; BRI, Behavioral Regulation Index; BRIEF, Behavior Rating Inventory of Executive Func-
tion; COWAT, Controlled Oral Word Association Test; CPT, Continuous Performance Test, Second Edition; DT, Divided Attention; GEC, Global
Executive Composite; ICC, Intraclass correlation coefficient; M, Mean; MCI, Metacognition Index; PAL, Paired Associated Learning; RT, Reaction
Time; SOC, Stockings of Cambridge; SST, Stop Signal Task; SWM, Spatial Working Memory; N/A, Normative reference data not available.
1Raw score.
2T score.
3Age scaled score.
4Summary score.
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deficits in participants with NF1. All baseline cognitive
outcomes were significantly below population reference
data with particularly large deficits seen on sustained and
divided attention measures from the TEA-Ch, confirming
attention as a key cognitive deficit in NF1.27 At the
behavioral level, inattentive and hyperactive ADHD symp-
toms and executive behaviors were rated as the most sig-
nificant problem areas. Consistent with previous
evidence,20 internalizing problems were less affected in
our cohort.
Second, this study revealed poor reliability of commonly
used cognitive outcomes in a real-life clinical trial setting.
This was particularly striking for the CANTAB tasks, which
all demonstrated test–retest reliabilities below acceptable
levels, and in some cases, reproducibility was very poor.
The variability noted across most cognitive tests was suffi-
ciently substantial to compromise outcome stability, limit-
ing the sensitivity of observed values to detect true change
in this population. Importantly, reliabilities were consider-
ably lower than published reliabilities in normative sam-
ples. As such, reliabilities of TEA-Ch subtests were
markedly lower (range, 0.30–0.63) than those reported in a
normative sample (range, 0.64–0.90).23 While direct com-
parison of individual CANTAB tasks is more difficult, data
from adult populations suggest higher reliabilities in neu-
rotypical samples (range, 0.60–0.68) compared with our
clinical trial (range, 0.10–0.61).28
These results raise important questions about the
source of the poor reproducibility. One possible account
is that executive tests of frontal lobe functioning are par-
ticularly sensitive to practice effects and are only valid
when they are novel, since performance on these evalua-
tions can rapidly improve as soon as an optimal strategy
is discovered (practice effect), but will improve less if no
strategy is found.28,29 However, there is no clear explana-
tion as to why strategy-driven practice effects would be
differentially affected in children with NF1. Poor reliabil-
ity was also observed on non-executive tests, including
Figure 1. Data reduction for neuropsychological measures conducted
using confirmatory factor analysis. The conceptual model shows how
we hypothesized our observed variables (parallelogram) related to the
four latent cognitive constructs (ellipse). For ease of presentation the
diagram shows standardized factor loadings but does not contain
error terms, cross loadings, or correlations between latent factors.
ADHD, attention-deficit/hyperactivity disorder; BRI, Behavioral
Regulation Index; BRIEF, Behavior Rating Inventory of Executive
Function; COWAT, Controlled Oral Word Association Test; CPT,
Continuous Performance Test, Second Edition; DT, Divided Attention;
GEC, Global Executive Composite; ICC, Intraclass correlation
coefficient; M, Mean; MCI, Metacognition Index; PAL, Paired
Associated Learning; RT, Reaction Time; SOC, Stockings of
Cambridge; SST, Stop Signal Task; SWM, Spatial Working Memory.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 2561
J. M. Payne et al. Cognitive Outcomes in Clinical Trials
our two primary outcomes, arguing against a strategy
effect. A further explanation for poor reproducibility in
this study is that the characteristic attention deficits in
NF1 result in variable performances and low stability
across all cognitive measures.27 In this instance, high vari-
ation in attention, impulse control, and perhaps motiva-
tion in clinical populations such as NF1 may critically
reduce the reliability and validity of observed cognitive
test scores such that they are unable to reliably quantify
the cognitive domain the test is purported to assess.
Third, we found that a theory-based reduction of our
cognitive and behavioral outcomes using CFA consider-
ably improved the reproducibility of our endpoints. CFA
in hypothesis-driven cognitive trials offers several advan-
tages. In measurement theory, each observed cognitive
test outcome reflects the underlying “true” score of the
unmeasured latent construct with measurement error.
CFA allows the loading of multiple observed values onto
an underlying latent construct while modeling measure-
ment error. As such, inferences about latent constructs
can be interpreted as if measurement error was
removed.30 Once error was accounted for in our model,
reproducibility of the executive functioning/attention,
visuospatial, and behavioral latent factors exceeded
acceptable levels for clinical trials. Critically,
reproducibility of these latent factors improved despite
the background of unreliable observed data.
Fourth, applicability and utility of our model was
demonstrated by the consistent range of effect sizes across
the reanalyzed efficacy data. Analysis of the three cogni-
tive latent variables suggested small, uniform, but non-
significant effects of lovastatin across all cognitive
domains and that there is no clinical benefit of lovastatin.
However, the consistency of treatment effects was consid-
erably increased compared to previously reported effects
using observed cognitive test scores,5 demonstrating the
advantages of data reduction and error modelling with
CFA. The uniformity of treatment effects favoring lovas-
tatin raise the possibility that statin therapy produced
cognitive effects somewhat analogous to the results
reported in preclinical trials,1 but that the effect size was
too small to yield statistical and clinical significance.
While we do not recommend lovastatin as a treatment
for cognitive deficits based on these results, our analyses
suggest that proof-of-concept trials in genetic conditions
such as NF1 should not be considered futile, and that
variables, such as outcome measures utilized, sample size,
as well as the dose, length and age of treatment, need to
be carefully considered in pre-trial therapeutic analyses.
Other novel surrogate outcome measures, such as
Table 3. Test–retest effects of latent cognitive and behavioral domains from the intention to treat placebo group1.
Total complete case
population
n
Test-retest effects, placebo group only
Baseline Baseline 16 weeks
ICCM SD M SD M SD
Latent variable
EF/attention 0.01 0.23 50 0.02 0.25 0.04 0.24 0.83
Visuospatial 0.04 0.38 50 0.02 0.37 0.08 0.41 0.78
Memory 0.02 0.48 50 0.03 0.45 0.07 0.39 0.66
Behavior 0.03 0.51 50 0.04 0.53 0.02 0.53 0.84
Abbreviations: EF, Executive functioning; ICC, Intraclass correlation coefficient; M, Mean; SD, Standard deviation.
1Multiple imputation applied to all placebo cases with baseline data (20 replications).
Table 4. Between group comparisons at 16 week using latent cognitive and behavioral domains from the intention to treat population.
Outcome
Control Lovastatin
b 95%CI P d 95%CI
Week 0 Week 16 Week 0 Week 16
n M SD M SD n M SD M SD
Latent variable
EF/attention 50 0.02 0.25 0.03 0.24 54 0.01 0.19 0.03 0.21 0.04 0.02 to 0.09 0.174 0.26 0.13 to 0.65
Visuospatial 50 0.02 0.37 0.08 0.40 54 0.04 0.39 0.04 0.41 0.07 0.04 to 0.17 0.208 0.24 0.14 to 0.63
Memory 50 0.03 0.45 0.07 0.40 54 0.03 0.50 0.07 0.55 0.11 0.05 to 0.27 0.184 0.26 0.12 to 0.65
Behavior 50 0.04 0.53 0.03 0.54 54 0.00 0.47 0.00 0.53 0.05 0.09 to 0.19 0.474 0.14 0.24 to 0.53
Abbreviations: EF, Executive functioning; M, Mean; SD, Standard deviation; d, Cohen’s d.
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biomarker assessments and functional neuroimaging,31
may prove more sensitive to change than cognitive tests.
Interestingly, the consistent effects across all cognitive
domains also suggest that any benefits of targeted treat-
ments in NF1 may not necessarily be confined to cogni-
tive tasks attempting to replicate murine behavioral
paradigms, or indeed to a particular cognitive domain.
Rather, cognitive domains and outcomes selected should
focus on areas of high clinical relevance to the NF1 popu-
lation.
There are several critical lessons from this study which
should be instructive to guide future cognitive clinical tri-
als. The inherent variability on cognitive testing in clinical
cohorts such as NF1 suggest that a single observed end-
point to estimate a cognitive ability is likely not appropri-
ate. Poor reliability reduces statistical power, which calls
for a substantial increase in sample size (not cost effective
or feasible for rarer disorders), or an unacceptably high
increase in the risk of false-positive or negative results,
which may have resulted in false-positive findings in pre-
vious trials.5,6,15 Before developing a clinical trial proto-
col, we strongly recommend piloting potential cognitive
outcomes at multiple time points in an untreated clinical
group to provide (1) base rates of deficits, (2) repro-
ducibility of the specific cognitive endpoints and (3) valu-
able data on reliability to inform sample size calculations
for clinical trials. Given specific cognitive tests are unli-
kely to return adequate reliability using observed test
scores, investigators should consider applying targeted
batteries of tasks and data reduction techniques, such as
CFA, to decrease the number of comparisons made and
reduce measurement error, thereby maximizing the repro-
ducibility of cognitive outcomes.
It is also important to reflect on these recommenda-
tions within the context of the US Food and Drug
Administration (FDA) Regulatory Standards used for
approving new drugs. While specific guidance regarding
observed versus latent performance outcome variables are
not provided, the FDA stipulates that the study protocol
and report of results should explain the variables mea-
sured, the methods of observation, and the criteria used
to assess response. Importantly, the assessment methods
should also be reliable.32 Thus in order to retain the
integrity of a priori reporting of methodology with the
study protocol and on clinical trial registries, it is essential
that the planned treatment of cognitive data be docu-
mented before trial commencement and that the choice
of cognitive tasks, as well as their theoretical grouping, is
guided by current conceptual models. It is also important
that cognitive endpoints are sensitive to intervention. To
this end, multifactorial scores that fully or partially rely
on crystalized abilities, such as full scale IQ, are not rec-
ommended as cognitive endpoints for shorter-term trials
(e.g., 16 weeks),33 as the abilities they measure (learned
knowledge and facts based on experience) are likely to
require >12 months to demonstrate change.
When interpreting the current results, it is important
to consider that test-retest reliability was assessed within a
placebo condition. While it is possible that a genuine pla-
cebo effect influenced reliability coefficients,34 our analy-
ses retain the distinct advantages of examining data from
a realistic clinical trial setting using a blinded, randomized
sample. Importantly however, we have demonstrated here
that despite any potential placebo effects, test-retest relia-
bility of cognitive outcomes can be considerably improved
through the application of careful, theory-driven data
reduction methods.
In conclusion, this study highlights the importance of
reliable cognitive endpoints in clinical trials. To improve
translation from preclinical studies, future clinical trials
will need to adopt methodologies that overcome the limi-
tations of cognitive assessment. Although the results for
this study are specific for NF1, the methods and recom-
mendations discussed are likely to be relevant for other
neurodevelopmental disorders, including autism and
ADHD.
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